Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2.


Journal

International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568

Informations de publication

Date de publication:
2022
Historique:
received: 14 08 2022
accepted: 14 08 2022
entrez: 20 10 2022
pubmed: 21 10 2022
medline: 22 10 2022
Statut: epublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 sequentially enrolled hospitalized patients with COVID-19-associated pneumonia from Brescia, Italy using the VirScan phage-display method to characterize circulating antibodies binding to 96,179 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection was associated with a marked increase in immune antibody repertoires against many known pathogenic and non-pathogenic human viruses. This antiviral antibody response was linked to longitudinal trajectories of disease severity and was further confirmed in additional 125 COVID-19 patients from the same geographical region in Northern Italy. By applying a machine-learning-based strategy, a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival was developed and validated. These results provide a basis for understanding the role of memory B-cell repertoire to viral epitopes in COVID-19-related symptoms and suggest that a unique anti-viral antibody repertoire signature may be useful to define COVID-19 clinical severity.

Identifiants

pubmed: 36263161
doi: 10.7150/ijbs.78002
pii: ijbsv18p5591
pmc: PMC9576512
doi:

Substances chimiques

Antiviral Agents 0
Epitopes 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

5591-5606

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Crit Rev Immunol. 2018;38(1):17-62
pubmed: 29717662
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Autoimmun Rev. 2020 Aug;19(8):102597
pubmed: 32535093
J Clin Invest. 2015 Jun;125(6):2228-33
pubmed: 25893595
Nat Med. 1997 Dec;3(12):1394-7
pubmed: 9396611
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Nat Rev Microbiol. 2011 Apr;9(4):254-64
pubmed: 21407242
Sci Transl Med. 2015 Apr 1;7(281):281ra43
pubmed: 25834109
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503877
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Science. 2020 May 8;368(6491):638-642
pubmed: 32234804
Science. 2015 Jun 5;348(6239):aaa0698
pubmed: 26045439
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Rev Dis Primers. 2018 Aug 2;4(1):11
pubmed: 30072738
Immunol Rev. 2018 May;283(1):138-149
pubmed: 29664566
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Nat Rev Immunol. 2009 Apr;9(4):246-58
pubmed: 19319143
Cancer Cell. 2019 Oct 14;36(4):418-430.e6
pubmed: 31588021
Cancer Res. 2010 Dec 15;70(24):10202-12
pubmed: 21159642
Immunity. 2015 Jul 21;43(1):132-45
pubmed: 26187412
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15193-15199
pubmed: 32522874
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Nat Rev Immunol. 2020 Jul;20(7):442-447
pubmed: 32528136
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8227-32
pubmed: 9653169
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Cell. 2020 Jul 23;182(2):317-328.e10
pubmed: 32526205
Science. 2019 Nov 1;366(6465):599-606
pubmed: 31672891
Immunity. 2015 May 19;42(5):805-13
pubmed: 25992857
Cell Rep Med. 2020 Oct 20;1(7):100123
pubmed: 32995758
Nat Rev Rheumatol. 2020 Aug;16(8):413-414
pubmed: 32499548
Ann Neurol. 2006 Mar;59(3):499-503
pubmed: 16502434
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508

Auteurs

Limin Wang (L)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892.
These authors contributed equally.

Julián Candia (J)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892.
These authors contributed equally.

Lichun Ma (L)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892.
These authors contributed equally.

Yongmei Zhao (Y)

CCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Frederick National Laboratory for Cancer Research, 8560 Progress Drive, Frederick, Maryland 21701.
These authors contributed equally.

Luisa Imberti (L)

CREA Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.

Alessandra Sottini (A)

CREA Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.

Eugenia Quiros-Roldan (E)

Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy.

Kerry Dobbs (K)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Peter D Burbelo (PD)

National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland 20892.

Jeffrey I Cohen (JI)

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Ottavia M Delmonte (OM)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Marshonna Forgues (M)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892.

Hui Liu (H)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Helen F Matthews (HF)

Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Elana Shaw (E)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Michael A Stack (MA)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Sarah E Weber (SE)

Section of Molecular Development of the Immune System, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Yu Zhang (Y)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Andrea Lisco (A)

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Irini Sereti (I)

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Helen C Su (HC)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Luigi D Notarangelo (LD)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.

Xin Wei Wang (XW)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892.
Liver Cancer Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892.
Lead Contact.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH